Skip to main content

Table 1 Patient demographics

From: Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology

 

DM (17 pts.)

Non-DM (44 pts.)

p

Age (years)

62.2 ± 7.1

62.0 ± 10.9

0.96

Men

12 (70.6%)

35 (79.5%)

0.51

Arterial hypertension

17 (100%)

39 (88.6%)

0.31

Current smoking

4 (23.5%)

15 (34.1%)

0.54

MI in past

7 (50%)

20 (54.1%)

0.8

Statin naive

3 (17.6%)

10 (22.7%)

0.98

Beta blockers

16 (94.1%)

28 (63.6%)

0.02

ACEI

15 (88.2%)

36 (81.8%)

0.71

Baseline Ch (mmol/l)

4.21 ± 0.75

4.31 ± 1.22

0.69

Follow-up Ch (mmol/l)

3.79 ± 0.99

3.35 ± 0.99

0.13

Change of Ch (mmol/l)

− 0.42 ± 0.89

− 0.97 ± 1.45

0.09

Baseline LDLc (mmol/l)

2.42 ± 0.53

2.46 ± 1.04

0.86

Follow-up LDLc (mmol/l)

2.12 ± 0.91

1.8 ± 0.66

0.21

Change of LDLc (mmol/l)

− 0.3 ± 0.52

− 0.66 ± 1.09

0.18

Baseline HDLc (mmol/l)

1.08 ± 0.38

1.23 ± 0.3

0.14

Follow-up HDLc (mmol/l)

1.09 ± 0.38

1.23 ± 0.27

0.19

Change of HDLc (mmol/l)

0.02 ± 0.52

− 0.01 ± 0.24

0.88

Baseline TAG (mmol/l)

1.59 ± 0.74

1.50 ± 0.88

0.4

Follow-up TAG (mmol/l)

1.52 ± 0.95

1.21 ± 0.52

0.22

Change TAG (mmol/l)

− 0.07 ± 0.96

− 0.29 ± 0.84

0.42

apo A (mmol/l)

0.08 ± 0.15

1.36 ± 0.32

0.16

apo B (mmol/l)

− 0.08 ± 0.22

− 0.13 ± 0.33

0.54

Baseline hs-CRP (mg/l)

2.28 ± 2.53

3.14 ± 4.31

0.49

Follow-up hs-CRP (mg/l)

4.87 ± 5.5

3.43 ± 4.0

0.3

Change of hs-CRP (mg/l)

2.6 ± 4.24

0.29 ± 5.1

0.13

Baseline glycemia (mmol/l)

7.04 ± 2.41

5.59 ± 0.78

0.0009

Follow-up glycemia (mmol/l)

7.51 ± 2.1

5.67 ± 0.78

< 0.0001

Change of glycemia (mmol/l)

0.04 ± 2.83

− 0.18 ± 1.45

0.69

  1. MI myocardial infarction, ACEI angiotensin-converting enzyme inhibitors, Ch cholesterol, LDLc low density lipoprotein cholesterol, HDLc high density lipoprotein cholesterol, TAG triacyl glyceroles, apo A apolipoprotein A, apo B apolipoprotien B, hs-CRP high sensitive C reactive protein